A Randomized, Blinded, Placebo-Controlled, Multicenter, Dose-Escalating Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BG9924 When Given in Combination With Methotrexate to Subjects With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to DMARD Therapy

This Phase 2a study is designed to evaluate the safety and tolerability of multiple
subcutaneous (SC) doses of BG9924, administered in a cohort dose-escalation fashion, in
patients with active rheumatoid arthritis (RA) who have had an inadequate response to therapy
with disease-modifying anti rheumatic drugs (DMARDs) and who may have undergone anti-TNF
therapy. This study will assist with dose selection for further planned Phase 2 studies.